COURSE UNIT TITLE

: PHARMACOGENETICS

Description of Individual Course Units

Course Unit Code Course Unit Title Type Of Course D U L ECTS
MOT 6037 PHARMACOGENETICS ELECTIVE 1 0 0 3

Offered By

Molecular Medicine

Level of Course Unit

Third Cycle Programmes (Doctorate Degree)

Course Coordinator

PROFESSOR DOCTOR MUKADDES GÜMÜŞTEKIN

Offered to

CLINICAL DRUG RESEARCH
Molecular Medicine

Course Objective

Pharmacogenetics focuses on changes observed in drug kinetics and patient responses to drugs affected by personal and ethnic genetic variations. Purpose of this course is to learn general information and concepts about pharmacology and pharmacogenetics, to have information about changes observed in drug effects, pharmacokinetics, and pharmacodynamics affected by genetic factors, to have information about pharmacogenetics of drug transporters, to evaluate and identify genetic characteristics changing effects of the drugs used for treatment and diagnosis, to interpret the relation between drug adverse effects and pharmacogenetics, to understand the importance of pharmacogenetics in clinical situations and of personalized treatment, and to transfer the knowledge obtained in this course in a systematic way.

Learning Outcomes of the Course Unit

1   be able to define the concepts and general information about pharmacogenetics
2   be able to identify genetic variations of the enzymes responsible for drug metabolism
3   be able to understand the mechanisms changing the action and bioavailability of drugs at the molecular level
4   be able to to evaluate and identify genetic characteristics changing effects of the drugs used for treatment and diagnosis
5   be able to know and identify the molecules that mediate the adverse effects of drugs and, establish the relationship with pharmacogenetics, if any.

Mode of Delivery

Face -to- Face

Prerequisites and Co-requisites

None

Recomended Optional Programme Components

None

Course Contents

Week Subject Description
1 Introduction to Pharmacology Definition and Basic Concepts
2 Pharmacogenetics and pharmacogenomics Definition and Basic Concepts
3 Personalized treatments and pharmacogenetics
4 Changes in drug pharmacokinetics due to genetic factors 1 - Genetic variations of Phase I enzymes (CYP2D6, CYP2C19 CYP2C9, CYP2C8, CYP2A6, CYP1A2, CYP2B6, CYP3A polymorphisms ve changes observed in drug pharmacokinetics)
5 Changes in drug pharmacokinetics due to genetic factors 2 - Genetic variations of Phase II enzymes (NAT-2, UGT-1A1, GST and other polymorphisms and changes observed in drug pharmacokinetics)
6 Case examples on changes in drug pharmacokinetics due to genetic factors
7 Pharmacogenetics of drug transporters -1 - Pharmacogenetics of efflux transporters ( ABC1 and other ABC family members)
8 Pharmacogenetics of drug transporters -2 - Pharmacogenetics of uptake transporters (Organic anion and cation transport molecules, OATP1B1 and others, OCT1 and others)
9 Case examples on pharmacogenetics of drug transport molecules and its effect on drugs
10 Changes in drug pharmacodynamics due to genetic factors - 1 - G6PDH deficiency and drugs - Warfarin tolerance - Hereditary methemoglobinemia and hemoglobinopathies - Corticosteroid-induced glaucoma crisis - Inability to detect bitter taste of phenylthiourea and phenylthiocarbamide (taste blindness) and smell blindness - Vitamin D-resistant rickets - Malignant hyperthermia and muscle rigidity
11 Changes in drug pharmacodynamics due to genetic factors - 2 - Polymorphisms of neurotransmitter-associated receptors and other functional molecules (Genetic variations of adrenergic, dopaminergic, serotoninergic receptors, dopamine and serotonin transport molecules and ion channels on the membrane of neuronal endings and their effects on drugs)
12 Changes in drug pharmacodynamics due to genetic factors - 3 - Changes in cancer treatment outcomes due to somatic gene variations of the tumor tissue (EGFR mutation and gefitinib treatment etc.)
13 Case examples on changes in drug pharmacodynamics due to genetic factors
14 Genetic differences of the inhibition and inducibility characteristics of the enzymes responsible for drug metabolism and related conditions.
15 Practical importance of the subject, reflection on clinic, and pharmacogenetic tests.
16 Final exam

Recomended or Required Reading

Textbook(s):
1. Goodman & Gilman's The Pharmacological Basis of Therapeutics , 2012
2. Rang and Dale s Pharmacology, 7th. Edition, 2011
3. Medicinal Chemistry, Gareth Thomas, 2nd. Edition, 2007
4. Basic and Clinical Pharmacology. B.Katzung. Appleton & Lange. 11th ed. 2007.
5. The Cell: A Molecular Approach, Geoffrey M. Cooper and Robert E. Hausman, 5th Edition, 2009
6. Pharmacology Primer, 3rd ed. / Terry Kenakin. 2009.
7. Pharmacology: Principles and practice. Bachmann, Kenneth A. Elsevier/Academic Press, 2009

Supplementary Book(s):
1. Rasyonel Tedavi Yönünden Tıbbi Farmakoloji. S. Oğuz Kayaalp. Pelikan Yayıncılık. 13. Baskı, 2012

Planned Learning Activities and Teaching Methods

Assessment Methods

SORTING NUMBER SHORT CODE LONG CODE FORMULA
1 PRF PERFORMANCE
2 FIN FINAL EXAM
3 FCG FINAL COURSE GRADE PRF * 0.40+ FIN* 0.60
4 RST RESIT
5 FCGR FINAL COURSE GRADE PRF * 0.40+ RST* 0.60


*** Resit Exam is Not Administered in Institutions Where Resit is not Applicable.

Further Notes About Assessment Methods

Students are expected to make power point presentation related to a subject from pharmacogenetics.

Assessment Criteria

Students achievement will be measured by passing the final exam and making power point presentation related to a subject from course program.

Language of Instruction

Turkish

Course Policies and Rules

To be announced.

Contact Details for the Lecturer(s)

gumustek@deu.edu.tr, telephone number: 4123906

Office Hours

To be announced.

Work Placement(s)

None

Workload Calculation

Activities Number Time (hours) Total Work Load (hours)
Lectures 15 1 15
Preparation before/after weekly lectures 15 2 30
Preparation for Final Exam 1 19 19
Preparing Presentations 1 10 10
Final 1 1 1
TOTAL WORKLOAD (hours) 75

Contribution of Learning Outcomes to Programme Outcomes

PO/LOPO.1PO.2PO.3PO.4PO.5PO.6PO.7PO.8PO.9PO.10
LO.13333333333
LO.23333333333
LO.33333333333
LO.43333333333
LO.53333333333